An 80-year-old man received immunotherapy with intravenous infusion of camrelizumab 0.2 g (d1, 21 days as a circle) because of tumor progression of left lung adenocarcinoma after 6 cycles of chemotherapy. One week after the first intravenous infusion of camrelizumab, the patient developed multiple rash with pruritus on the trunk, and it was improved after symptomatic treatment. Five days after the second intravenous infusion of camrelizumab combined with apatinib, the patient reappeared a large area of rash with pruritus on the head, face, trunk and limbs, and was diagnosed as having exanthematous drug eruption. Then camrelizumab and apatinib were stopped, and glucocorticoid and antiallergic treatment were given. Ten days later, the rash was almost disappeared.